Optoceutics is developing cutting-edge technologies to help fight neurodegenerative diseases and mental health disorders. It was established in 2018 as a university spin-out based on a world patent from collaborative research at Danish Technical University (DTU) and University of California Berkeley (UCB) on the medical effects of masked light brain stimulation.
In particular, Optoceutics is investigating new approaches to Gamma brain wave stimulation for Alzheimer’s Disease. They are conducting a clinical study to investigate the potential effect of masked 40 Hz flickering light on Alzheimer’s disease patients. We are also collaborating on measuring masked light stimulation’s effects on major depression and anxiety disorders.